Neutralisation of the anti-coagulant effects of heparin by histones in blood plasma and purified systems

Thrombosis and Haemostasis

Volumn 115, Issue 3, 2016, Pages 591-599

  Longstaff, Colin ^a   Hogwood, John ^a   Gray, Elaine ^a   Komorowicz, Erzsébet ^b   Varjú, Imre ^b   Varga, Zoltán ^c   Kolev, Krasimir ^b  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

APTT; DNA; Heparin; Histones; Neutrophil extracellular traps

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; HEPARIN; HISTONE; LOW MOLECULAR WEIGHT HEPARIN; ANTICOAGULANT AGENT; COAGULATING AGENT; DNA; FIBRIN; PROTEIN BINDING;

ARTICLE; BLOOD CLOTTING; HUMAN; IC50; INFLAMMATION; PARTIAL THROMBOPLASTIN TIME; PLASMA; PRIORITY JOURNAL; RADIATION SCATTERING; SCANNING ELECTRON MICROSCOPY; VISCOELASTICITY; BLOOD; CHEMISTRY; ELASTICITY; HEMOSTASIS; SEPSIS; SURFACE PLASMON RESONANCE; THROMBOSIS; VISCOSITY;

ANTICOAGULANTS; ANTITHROMBINS; BLOOD COAGULATION; COAGULANTS; DNA; ELASTICITY; FIBRIN; HEMOSTASIS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HISTONES; HUMANS; INHIBITORY CONCENTRATION 50; PARTIAL THROMBOPLASTIN TIME; PLASMA; PROTEIN BINDING; SEPSIS; SURFACE PLASMON RESONANCE; THROMBOSIS; VISCOSITY;

EID: 84959520425     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-03-0214     Document Type: Article

References (46)

1. Esmon CT. Molecular circuits in thrombosis and inflammation. Thromb Hae-most 2013; 109: 416-420.
2. Martinod K, Wagner DD. Thrombosis: tangled up in NETs. Blood 2014; 123: 2768-2776.
3. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nature Rev Immunol 2013; 13: 34-45.
4. Borissoff JI, ten Cate H. From neutrophil extracellular traps release to thrombo­sis: an overshooting host-defense mechanism? J Thromb Haemost 2011; 9:1791-1794.
5. Brill A, Fuchs TA, Savchenko AS, et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost 2012; 10: 136-144.
6. Borissoff JI, Joosen IA, Versteylen MO, et al. Elevated levels of circulating DNA and chromatin are independently associated with severe coronary athero­sclerosis and a prothrombotic state. Arterioscler Thromb Vasc Biol 2013; 33:2032-2040.
7. De Meyer SF, Suidan GL, Fuchs TA, et al. Extracellular chromatin is an impor­tant mediator of ischemic stroke in mice. Arterioscler Thromb Vasc Biol 2012; 32: 1884-1891.
8. Demers M, Krause DS, Schatzberg D, et al. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc Natl Acad Sci USA 2012; 109: 13076-13081.
9. Tufano A, Di Capua M, Coppola A, et al. The infectious burden in atherothrom-bosis. Semin Thromb Hemost 2012; 38: 515-523.
10. Xu J, Zhang X, Pelayo R, et al. Extracellular histones are major mediators of death in sepsis. Nat Med 2009; 15: 1318-1321.
11. Huang H, Evankovich J, Yan W, et al. Endogenous histones function as alarmins in sterile inflammatory liver injury through Toll-like receptor 9 in mice. Hepa-tology 2011; 54: 999-1008.
12. Thomas GM, Carbo C, Curtis BR, et al. Extracellular DNA traps are associated with the pathogenesis of TRALI in humans and mice. Blood 2012; 119:6335-6343.
13. Doring Y, Manthey HD, Drechsler M, et al. Auto-antigenic protein-DNA com­plexes stimulate plasmacytoid dendritic cells to promote atherosclerosis. Circu­lation 2012; 125: 1673-1683.
14. de Boer OJ, Li X, Teeling P, et al. Neutrophils, neutrophil extracellular traps and interleukin-17 associate with the organisation of thrombi in acute myocardial infarction. Thromb Haemost 2013; 109: 290-297.
15. Longstaff C, Varju I, Sotonyi P, et al. Mechanical stability and fibrinolytic resis­tance of clots containing fibrin, DNA, and histones. J Biol Chem 2013; 288:6946-6956.
16. Gansler J, Jaax M, Leiting S, et al. Structural requirements for the procoagulant activity of nucleic acids. PLoS One 2012; 7: e50399.
17. Siri A, Balza E, Carnemolla B, et al. DNA-binding domains of human plasma fi-bronectin. pH and calcium ion modulation of fibronectin binding to DNA and heparin. Eur J Biochem 1986; 154: 533-538.
18. Fuchs TA, Bhandari AA, Wagner DD. Histones induce rapid and profound thrombocytopenia in mice. Blood 2011; 118: 3708-3714.
19. Ammollo CT, Semeraro F, Xu J, et al. Extracellular histones increase plasma thrombin generation by impairing thrombomodulin-dependent protein C acti­vation. J Thromb Haemost 2011; 9: 1795-1803.
20. Ward CM, Tetaz TJ, Andrews RK, et al. Binding of the von Willebrand factor A1 domain to histone. Thromb Res 1997; 86: 469-477.
21. Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science 2004; 303: 1532-1535.
22. Abrams ST, Zhang N, Manson J, et al. Circulating histones are mediators of trauma-associated lung injury. Am J Resp Crit Care Med 2013; 187: 160-169.
23. Saffarzadeh M, Juenemann C, Queisser MA, et al. Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of hi-stones. PLoS One 2012; 7: e32366.
24. Fuchs TA, Brill A, Duerschmied D, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA 2010; 107: 15880-15885.
25. Napirei M, Ludwig S, Mezrhab J, et al. Murine serum nucleases--contrasting ef­fects of plasmin and heparin on the activities of DNase1 and DNase1-like 3 (DNase1l3). FEBS J 2009; 276: 1059-1073.
26. Wildhagen KC, Garcia de Frutos P, Reutelingsperger CP, et al. Nonanticoagulant heparin prevents histone-mediated cytotoxicity in vitro and improves survival in sepsis. Blood 2014; 123: 1098-1101.
27. Zeerleder S, Zwart B, Wuillemin WA, et al. Elevated nucleosome levels in sys­temic inflammation and sepsis. Crit Care Med 2003; 31: 1947-1951.
28. Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 1: Heparin. American Heart Association. Circulation 1994; 89: 1449-1468.
29. Gresele P, Busti C, Paganelli G. Heparin in the prophylaxis and treatment of ve­nous thromboembolism and other thrombotic diseases. In: Heparin-a century of progress. Springer-Verlag 2012; pp. 179-209.
30. Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American Col­lege of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edi­tion). Chest 2008; 133: 141S-159S.
31. Nagasawa K, Inoue Y, Kamata T. Solvolytic desulfation of glycosaminoglycuron-an sulfates with dimethyl sulfoxide containing water or methanol. Carbohydrate Res 1977; 58: 47-55.
32. Whitton C, Sands D, Lee T, et al. A reunification of the US („NIH") and Inter­national Unit into a single standard for Thrombin. Thromb Haemost 2005; 93:261-266.
33. Varju I, Longstaff C, Szabo L, et al. DNA, histones and neutrophil extracellular traps exert anti-fibrinolytic effects in a plasma environment. Thromb Haemost 2015; 113: 1289-1298.
34. Pal PK, Starr T, Gertler MM. Neutralization of heparin by histone and its subfrac-tions. Thromb Res 1983; 31: 69-79.
35. Semeraro F, Ammollo CT, Morrissey JH, et al. Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4. Blood 2011; 118: 1952-1961.
36. Christophorou MA, Castelo-Branco G, Halley-Stott RP, et al. Citrullination regu­lates pluripotency and histone H1 binding to chromatin. Nature 2014; 507:104-108.
37. Wang Y, Li M, Stadler S, et al. Histone hypercitrullination mediates chromatin de-condensation and neutrophil extracellular trap formation. J Cell Biol 2009; 184:205-213.
38. Yipp BG, Kubes P. NETosis: how vital is it? Blood 2013; 122: 2784-2794.
39. Hogg PJ, Jackson CM, Labanowski JK, et al. Binding of fibrin monomer and hepa­rin to thrombin in a ternary complex alters the environment of the thrombin cata­lytic site, reduces affinity for hirudin, and inhibits cleavage of fibrinogen. J Biol Chem 1996; 271: 26088-26095.
40. Evans PA, Hawkins K, Morris RH, et al. Gel point and fractal microstructure of in­cipient blood clots are significant new markers of hemostasis for healthy and anti-coagulated blood. Blood 2010; 116: 3341-3346.
41. Nenci GG, Parise P, Morini M, et al. Fibrin clots obtained from plasma containing heparin show a higher sensitivity to t-PA-induced lysis. Blood Coagul Fibrinolysis 1992; 3: 279-285.
42. Collen A, Smorenburg SM, Peters E, et al. Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro. Cancer Res 2000;60: 6196-6200.
43. Parise P, Morini M, Agnelli G, et al. Effects of low molecular weight heparins on fi­brin polymerization and clot sensitivity to t-PA-induced lysis. Blood Coagul Fibri-nolysis 1993; 4: 721-727.
44. Yeromonahos C, Marlu R, Polack B, et al. Antithrombin-independent effects of he-parins on fibrin clot nanostructure. Arterioscler Thromb Vasc Biol 2012; 32:1320-1324.
45. Smith SA, Morrissey JH. Polyphosphate enhances fibrin clot structure. Blood 2008; 112: 2810-2816.
46. Smith SA, Choi SH, Davis-Harrison R, et al. Polyphosphate exerts differential ef­fects on blood clotting, depending on polymer size. Blood 2010; 116: 4353-4359.